A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib

Castellano, GM; Aisner, J; Burley, SK; Vallat, B; Yu, HA; Pine, SR; Ganesan, S

Pine, SR (reprint author), Rutgers Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08901 USA.

JOURNAL OF THORACIC ONCOLOGY, 2019; 14 (11): 1982

Abstract

Introduction: Osimertinib is an effective third-generation tyrosine kinase inhibitor (TKI) for EGFR-mutant lung cancers. However, treatment for patien......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索